deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02769481

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin

Sponsor: Theracos

Conditions Type 2 Diabetes Mellitus
Interventions Bexagliflozin Glimepiride Placebo for Bexagliflozin Placebo for Glimepiride
Updated 18 times since 2017 Last updated: May 25, 2021 Started: Aug 15, 2016 Primary completion: Jun 14, 2019 Completion: Jun 14, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by Theracos and has accumulated 18 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jul 2017 · 3 months · monthly snapshot~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jul 2019 · 8 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jul 2024 · 37 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jun 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jun 2021 [monthly]

    Completed PHASE3

▶ Show 13 earlier versions

  1. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE3

  2. Sep 2019 — Nov 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Jul 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Nov 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  5. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Jul 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Jul 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  11. Apr 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  12. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Theracos
Data source: Theracos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Aschaffenburg, Germany , Barcelona, Spain , Birmingham, United States , Bochnia, Poland , Bydgoszcz, Poland , Calabash, United States , Essen, Germany , Hamburg, Germany , Heidelberg, Germany and 27 more locations